ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Northwest Biotherapeutics Inc (QB)

Northwest Biotherapeutics Inc (QB) (NWBO)

0.273
-0.01641
(-5.67%)
Closed 06 February 8:00AM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

NWBO News

Official News Only

NWBO Discussion

View Posts
manibiotech manibiotech 50 seconds ago
So why don't you and Fox logic make that statement u der penalty of perjury .
I will do the same 
👍️0
Red_Right_Hand Red_Right_Hand 2 minutes ago
I think that announcing the restart of -Direct before -L approval will be spun by the SMA as an admission from the company that -L has failed and so they're restarting from scratch on a new asset. I think they think that too. So no matter what the actual current state of the Direct program is, we're not going to hear about it until we have final disposition on the -L MAA.
👍️0
Doc logic Doc logic 3 minutes ago
Investor082,

In the mean time off label use of the process to create vaccine from lysate will move forward since the process has been tested safely in ovarian cancer in a Phase 2 trial and other cancers already. Now wouldn’t that be a kicker with Sawston being a Specials center for ovarian cancer patients while L is approved for GBM and rGBM.
There is also no stopping two approved treatments from being used by clinicians for their patients whether the combo is approved or not so there is that and folks that want to actually have a chance to be cured will want this; ). Best wishes.
👍️0
WojD40 WojD40 5 minutes ago
I think it’s much more exciting than just Eden and Approval. Two combination trials were concluded early and data locked last autumn. We’ve not yet had Topline Data for these, even though the interim analysis was outstanding. It might be that our long rumoured partnership deals are with the companies involved, and conditional on the MHRA outcome.

The Company deciding to wait for these ducks to line up is a more credible narrative than the one offered up by my fellow keyboard warriors…that of incompetence and fraud…regardless of how much they moo about it.

We shall see in the next 90 days.
👍️ 1
flipper44 flipper44 12 minutes ago
I’m not getting paid, dummkopf, but I suspect you are.
👍️ 2
manibiotech manibiotech 14 minutes ago
Nope that's what the offer was
. And I don't know who the eff if mod
I I asked Doc Logic to state under penalty of perjury that he is not getting paid ... and you know by who all
🚽 1
flipper44 flipper44 16 minutes ago
Really? I could have sworn I spelled some words correctly today.
👍️0
eagle8 eagle8 21 minutes ago
nice score again the last 3 hours.
28 visible posts on my screen, the rest, 72 pieces!, have been from ignores for a long time.
👍️0
manibiotech manibiotech 22 minutes ago
And my offer is open to you also . Same offer as Doc Logic
You have been wrong 100 percent of the times 
👍️0
FeMike FeMike 26 minutes ago
Yes flip. That’s what I said. Right as always.
👍️0
flipper44 flipper44 28 minutes ago
Guess we’ll never know, but delusional Mike thinks hyping, by re-releasing the patent office’s prior DCVax-Direct news would send the stock soaring before MAA approval. 🙄

Weeee.
🎯 2 💯 2 🤣 1
FeMike FeMike 31 minutes ago
Hey flip, thanks for trying, but please try to keep up.

I didn’t say the patent news was gonna send the stock soaring.

You said that the patent news was the official restart of Direct. If that’s true, Linda should PR the official restart of Direct. That news would send the stock soaring.

I don’t believe you. I don’t think the patent being granted was the official restart of direct. I think you’re full of shit. So I think that’s why the restart of Direct wasn’t PRd, because it didn’t happen. Not because Linda Powerless is afraid of exwannabe, as you claim.
👍️ 1 💯 1 🚽 1 🪠 1
flipper44 flipper44 39 minutes ago
Plot line. Delusional FeMike.

Patent office releases DCVax-Direct news.
Mike wants Linda to hype it prior to maa DCVax-l approval. Delusional Mike thinks this would send the stock “soaring” to re-release and hype the patent office’s news prior to DCVax-l approval news.
🌏️ 1 🎯 1
FeMike FeMike 40 minutes ago
And right on cue, the usual plot line for an argument with flipper plays out.

Flipper: says something stupid
Mike: calls him out
Flipper: can’t defend his position so resorts to insults and stops discussing said topic

Rinse, repeat.
👍️ 2 💯 1 🚽 1 🪠 1
flipper44 flipper44 43 minutes ago
You’re delusional sir, that wasn’t his question.
👍️0
FeMike FeMike 47 minutes ago
His question actually was:

If the patent news was, as you claim, the official restart of the Direct program, why did LP not PR the restart of the direct program.

The good news isn’t the patent. The good news would be Direct restarting (and no, the patent being granted does not signal the restart of Direct, just like the MAA being cemented didn’t signal the finalization of combo trials)

And no, regardless of what the news is, the European patent office doesn’t get to break it. NWBO does.
🚽 1 🪠 1
antihama antihama 49 minutes ago
MHRA MAA approval coupled w guidance on sales/non-dilutive funding and/or partnerships is the key that unlocks the share price. New clinical trials are exciting but hey you know "It's the money honey"
👍️ 1 💯 1
flipper44 flipper44 55 minutes ago
Space cadet #2.
👍️0
manibiotech manibiotech 57 minutes ago
lol ... agree
It's getting too comical
👍️0
improving improving 1 hour ago
Sure Kid.
True:
"DCVax-L is anticipated to be the top revenue-generating therapy among all..."
Source - https://www.openpr.com/news/3671194/high-grade-glioma-market-2034-epidemiology-trends
Delveinsight Business Research.

You do realize there is some fairly pricey litigation in the SDNY against some rather large Market Makers for share price manipulation? It made the papers -spoofing, naked shorting, bad stuff. Everyone knows the scuMMers are keeping the share price lid on, you better than most I imagine.

False:
"Keep on patting this management team on the back but the market has made it clear, they don[']t find them credible."
The market does find DCVax credible-which is the most likely reason you are here.
👍️0
flipper44 flipper44 1 hour ago
Space cadet #1, the patent “news” on DCVax-Direct was “released” by the European patent office. That’s who gets to break the good news.

(Jack’s question, which I responded to, was why didn’t she “dress up” that news prior to an MAA approval)
🎯 1 👍️ 1 🔑 1 🙂 1
scotty3371 scotty3371 1 hour ago
She isn't doing anything wrong, she just sucks as a ceo. She seems very intelligent, but she is unable to make her shareholders money. Nwbo has become a boring 1.3 billion shares, 27 cents company that is completely dead. 


👍️ 2
FeMike FeMike 1 hour ago
Haha what a load of horse shit.

Yes, the reason NWBO isn’t releasing huge news that would send the share price soaring (in times of high dilution when they desperately need) it is because they are worried exwannabe on iHub is going to bash them for releasing good news.

Man you are bordering on dstock/danish dude level of delusion.
🎯 1 👍️ 3 😂 1 🚽 1 🪠 1
Steady_T Steady_T 1 hour ago
I think it unlikely that the evaluators will go through all 1.7 million pages. I would think that many of those pages are individual patient docs and other sorts of raw data. The evaluators will check some of that data to make sure that there are no improper aggregations. After that they will deal with the aggregated data and statistics.

Even after that, it is still a very large filing to evaluate.
👍️ 1
manibiotech manibiotech 1 hour ago
If they had anything in their pocket , volume and SP would have skyrocketed by now
They are full of s...
And cure of all cancers ...Lol
👍 1
Investor082 Investor082 2 hours ago
Now, you want to defend your buddy, but you have no idea what you are taking about, just like your $90M annual revenue BS!

Combos are not going to be approved for many years. They need to run a proper trial first. So Flaskworks excuse is BS. They don’t need Flaskworks for combo trials. They can run a trial with artisan method.

Also, Flaskworks commercial approval ain't happening in 2025.

So if a big pharma were to strike a deal with NWBO to run combo trial and then take the combo through commercialization (provided successful results), they don’t need to wait for Flaskworks at this time. They can start the trial with manual method. They will have at least 3-4 years before they have enough data from the clinical trial to be in a position to submit an application for the combo product to any regulatory agency.
👍️0
manibiotech manibiotech 2 hours ago
lol lol

👍️0
ilovetech ilovetech 2 hours ago
BOOM 💥 BAM! 💥 WHAM!!💥🎤
👍️ 2
Doc logic Doc logic 2 hours ago
Investor082,

Oh he believes it but the timing is likely influenced by Flaskworks as well so how the details and timing work out gets a little tricky without any update on Flaskworks. Combos aren’t going to be cheap so getting the cost of L down is extremely important not only for access to L but access to combos. Best wishes.
👍️0
LTR LTR 2 hours ago
Our hope is in the courts, not in politicians. Kenny will open his checkbook and all will be forgiven with Trump. Lets hope its not that way with the courts.
👍️ 1 💯 1 ✅️ 1
Investor082 Investor082 2 hours ago
You said this:
“DCVax licensed by larger BPs with CI or other complementary tech.”

— if you really believed this, then you would have no problem taking my bet, which was Big Pharma will partner with NWBO and inject some cash (either dilutive or non dilutive) before end of June 2025.

You have declined to take this bet on a number of occasions, which means you don’t believe in the statement above in quotes (which you stated in the earlier thread).
👍️0
DJPele DJPele 2 hours ago
Fund's won't clear until next Tuesday, so I personally wouldn't mind approval news by next Wednesday.
👍️ 1
learningcurve2020 learningcurve2020 2 hours ago
Yeah, that’s probably why she said “it’ll be when it’ll be” and held off submitting to NICE. 🙄
👍️0
Doc logic Doc logic 2 hours ago
DrHigh,

And just what in the annual reports, quarterlies or PRs are telling you that this is not essentially a pre revenue company concerned with market price manipulation to the point of securing a law firm to place a legal challenge on those companies suspected of being involved so that this company might actually be invested in by institutions?; ). What I have read is that they have not been anticipating profitability and are constantly issuing the standard disclaimer about uncertainty with regard to being a going concern that pre revenue companies make so that investors consider the risk carefully even though the science is strong and passed peer review by JAMA Oncology.
By the way, maybe you haven’t noticed but the “POTENTIAL” you point to has been mocked, denied, ridiculed and lied about while others attack the share price for so long that hey, maybe the potential just doesn’t matter anymore to investors that want to see the price cut loose from the grip of those who have enough influence over it to control it to a certain extent by shorting and spoofing while the company waits for news that will drive the price forward in spite of the manipulation because the potential, which was easily manipulated, has become a reality that can’t be; ). Best wishes.
👍️ 6 💯 3
KRISGO KRISGO 3 hours ago
When LP mentioned it, she likely believed we would have the approval in hand before the end of 2024, allowing them to start DCVAX Direct. However, they are still busy collaborating with the MHRA, and once approval is granted, they will make an announcement.
👍️ 1 🤑 1
RobotDroid RobotDroid 3 hours ago
Because she is a worthless POS.
👍️ 1 🚫 1 ❌️ 1
RobotDroid RobotDroid 3 hours ago
She has told so many lies it's hard to keep up.
👍️ 1
Jackxkr Jackxkr 3 hours ago
Just a bs response flip. No one ever ever ever accuses LP of pumping.
👍️ 1
RobotDroid RobotDroid 3 hours ago
Very very likely.
👍️ 1
RobotDroid RobotDroid 3 hours ago
New lows coming and proof that approval is far far away. This stinking POS stinks more every day, and nonmanagement stays inept and mute. The clown show continues...
👍️ 1 🚫 2 ❌️ 1
flipper44 flipper44 3 hours ago
Because nefarious creatures will wrongly interpret it as pumping and trying to distract from the MAA process. Ex, for instance, is already doing this.
👍️ 1 🤕 1 🤥 1
RobotDroid RobotDroid 3 hours ago
Wow, licking L Worthless boots is not a good look for Doc. Pure fiction, she is the worst ceo ever.
👍️0
Jackxkr Jackxkr 3 hours ago
Then why in hell doesn't she put out a NR and dress it up as to why they are restarting it.
👍️0
Jackxkr Jackxkr 3 hours ago
So what if lp doesn't know how to fight back against it she should step aside and let someone who does give it a go.
👍️0
RobotDroid RobotDroid 3 hours ago
And the boards most ignorant.
👍️ 1
flipper44 flipper44 3 hours ago
On January 31, 2025, DCVax-Direct, (after previously receiving its optimization patent that goes to 2036, in other countries like the USA and Japan), also received that Patent Grant in Europe, which for patent purposes, also includes the United Kingdom.

I’ll take that as the official DCVax-Direct program restart.
🎯 6 🏆️ 2 👍️ 18 🔑 2 🚀 1 🤣 1
ilovetech ilovetech 3 hours ago
To those who can't accept manipulation or worse, paid to distract from it: https://x.com/metacollectiveG/status/1886601838494912522?t=K_Vqryz73XeewEWlZsm1VA&s=19
👍 1
RobotDroid RobotDroid 3 hours ago
Now the dumbest post of the day. Ken can buy off the orange grifter with ease. For him, money talks, always. He could care less about the long suffering SH.
👍️ 1
KRISGO KRISGO 3 hours ago
We have three Wednesdays left this month.

Second, I took a look at where approvals tend to fall during each month. Excluding IRP approvals (which have a different process), approval announcements broke down this way:

- First week of the month (days 1-7): 1 approval (5.56%)
- Second week of the month (days 8-14): 2 approvals (11.11%)
- Third week of the month (days 15-21): 5 approvals (27.78%)
- Fourth week of the month (days 22-28): 9 approvals (50.00%)
- End of the month (days 29-31): 1 approval (5.56%)

As you can see, the majority of approvals came after the third week of the month, while the vast majority (83.33%) came during the second half of the month.

- Third, I took a look at which day of the week approvals tended to fall (again excluding IRP):

- 1 approval came on Monday (5.56%)
- 3 approvals came on Tuesday (16.67%)
- 10 approvals came on Wednesday (55.56%)
- 2 approvals came on Thursday (11.11%)
- 2 approvals came on Friday (11.11%)
👍️0
learningcurve2020 learningcurve2020 3 hours ago
Fax is down so transfer moving slow.
👍️0